Cell Line Development Market Report by Size & Share - 2027

[Research Report] The cell line development market was valued at US$ 4,160.42 million in 2019 and is projected to reach US$ 11,219.87 million by 2027; it is expected to grow at a CAGR of 13.3% from 2020 to 2027.

The cell line is an established cell culture, wherein the cells multiply in the apt growth medium and space for growth. Different cell lines are made from different cells. Cell lines enable stepwise alterations in the structure, physiology, and genetic makeup of cells under a customized environment. The cell line development market growth is mainly attributed to increasing adoption of regenerative medicines, rising prevalence of cancer across the globe, and soaring investments in R&D by pharmaceutical and biotechnology companies. Moreover, consistent research in drug discovery activities is further expected to foster market growth during the forecast period. However, the risk of cell line contamination is restricting the market growth.

North America has been witnessing growing number of COVID-19 cases since the viral outbreak. According to Worldometer, as of September 2, 2020, the number of cases has reached to 6,335,244, with 191,058 deaths, in the US. The pharmaceutical companies and research institution have shifted their research activities in finding vaccine for COVID-19, thereby putting the development of other therapeutics on hold. Moreover, many research organizations are struggling with a wide range of challenges such as reduced funding, cancelled fundraising events, and shelving projects due to economic uncertainty. Thus, the abovementioned factors are hindering the growth of the cell line development market, and the impact is likely to persist for a certain time period.

Lucrative Regions for Cell Line Development Market

Get more information on this report : Request Free Sample PDF

Market Insights

Increasing Adoption of Regenerative Medicines Drives Cell Line Development Market Growth

Regenerative medicines have the potential to replace or heal tissues as well as organs damaged due to various factors, such as age, disease, or trauma; they also help normalize congenital defects. Over the last quarter of a century there has been an emergence of a tissue engineering industry, which has now evolved into the broader area of regenerative medicines. Regenerative medicines are a rapidly growing interdisciplinary field with the involvement of engineering sciences to develop clinical therapies for maintenance, repair, replacement, and enhancement of biological functions. The cell line development is a crucial and invariable part of this field as it helps understand how to treat a wide range of medical conditions, from broken bones to neurodegenerative diseases. Further, the regenerative medicines use cell-based models that have the potential to help the researchers in early-intervention treatment for degenerative diseases and traumatic injuries. Thus, the rise in adoption of regenerative medicines is fostering the demand for cell line development in the coming years.
 

Type-Based Insights

Based on type, the cell line development market is segmented into primary cell lines, hybridomas, continuous cell lines, and recombinant cell lines. The recombinant cell line segment held the largest share of the market in 2019. However, the hybridomas segment is anticipated to register the highest CAGR during the forecast period. The growth of the market for recombinant cell lines is attributed to rising demand for recombinant proteins, increasing use of recombinant cell lines for biotherapeutics, and growing demand for toxicity testing.

Cell Line Development Market, by Type – 2019 and 2027

Get more information on this report : Request Free Sample PDF

Product-Based Insights

Based on product, the cell line development market is segmented into equipment, and media and reagent. The media and reagent segment held a larger share of the market in 2019. Moreover, it is anticipated to register a higher CAGR during the forecast period. The media contain crucial ingredients and compounds that regulate cell cycle. A culture medium consists of amino acids, inorganic salts, vitamins, glucose, and serum that act as precursors of hormones, growth factors, and attachment factors. Similarly, several reagents are used during the development of cell line.

Application-Based Insights

Based on application, the cell line development market is segmented into drug discovery, bioproduction, and tissue engineering. The bioproduction segment held the largest share of the market in 2019. The growth of the segment is attributed to the wide availability of cell lines for bioproduction. Many of the market players are offering cell lines for bioproduction purposes. For instance, Creative Biogene provides comprehensive services for generating bioproduction stable cell lines. However, the drug discovery segment is anticipated to register the highest CAGR during the forecast period.

Strategic Insights

Product launches, mergers and acquisitions, collaborations, and expansions are the commonly adopted strategies by various companies to expand their footprint worldwide and meet the growing demand by expanding their respective product portfolios. The players operating in the cell line development market adopted the product innovations strategy to cater to the changing customer demands around the world, which also permits them to maintain their brand name in a global market. In April 2019, Lonza launched CellBio Services, a comprehensive portfolio of unique, custom-made solutions designed to meet specific, individual research application needs.

Cell Line Development Market – by Type

• Primary Cell Line
• Hybridomas
• Continuous Cell Lines
• Recombinant Cell Line

Cell Line Development Market – by Product

• Equipment
• Media & Reagent

Cell Line Development Market – by Application

• Drug Discovery
• Bioproduction
• Tissue Engineering

Cell Line Development Market– by Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe
• Asia Pacific(APAC)
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of APAC
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA
• South and Central America (SCAM)
  • Brazil
  • Argentina
  • Rest of SCAM

Company Profiles

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Selexis SA (JSR Corporation)
• BioFactura, Inc.
• Corning Incorporated
• Sartorius AG
• Lonza
• GENERAL ELECTRIC
• LakePharma, Inc.
• WuXiAppTec Group